NCT07277270

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.

Conditions

• Neoplasms

Interventions

Type	Name	Description
DRUG	GSK5764227	Participants will receive GSK5764227.
DRUG	Bevacizumab	Participants will receive bevacizumab.
DRUG	Fluorouracil	Participants will receive fluorouracil.
DRUG	leucovorin	Participants will receive leucovorin.
DRUG	Enzalutamide	Participants will receive enzalutamide.

Timeline

• Start date: 2025-12-03
• Primary completion: 2026-07-13
• Completion: 2028-09-29
• First posted: 2025-12-11
• Last updated: 2026-01-07

Locations

6 sites across 3 countries: United States, Australia, Spain

Regulatory

• FDA-regulated drug study